Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Ítems similars

• ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
  per: Cummings, Jeffrey L., et al.
  Publicat: (2018)
• Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
  per: Yoshida, Kenta, et al.
  Publicat: (2020)
• Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
  per: Yang, Ting, et al.
  Publicat: (2019)
• Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays
  per: Schauer, Stephen P., et al.
  Publicat: (2018)
• Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ
  per: Meilandt, William J., et al.
  Publicat: (2019)